Although evidence regarding long-term management of CIDP is limited, patients benefiting from long-term IVIg treatment who become refractory to IVIg become responsive to the therapy again after a short course of plasma exchange.
Patients with very mild symptoms that do not significantly interfere with activities of daily living may not require treatment. However, therapy with corticosteroids or IVIg should be offered to patients with moderate or severe disability.
Immunosuppression may be required particularly in cases of atypical disease or long-term course, or when the response to corticosteroids, IVIg, or plasma exchange is inadequate.
Approximately two thirds of patients will need IVIg, and 15%-30% of patients require only a single course of IVIg.
Learn more about medication in CIDP treatment.
Editor's Recommendations
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Jafar Kafaie. Fast Five Quiz: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Management - Medscape - Jun 24, 2021.
Comments